Integrating radiosensitivity index and triple‐negative breast cancer subtypes reveals SERPINB5 as a radioresistance biomarker in triple‐negative breast cancer.

This article explores the development of predictive biomarkers for radiotherapy outcomes in triple-negative breast cancer (TNBC). The study integrates the Radiosensitivity Index (RSI) with the Fudan University Shanghai Cancer Center (FUSCC) TNBC classification to identify a specific TNBC subpopulation that exhibits radioresistance and an increased risk of local recurrence post-radiotherapy. The study identifies the SERPINB5 gene as a potential therapeutic target for radioresistance in high-risk TNBC patients. The research also reveals distinct immunological profiles in TNBC patients with radioresistant tumors, highlighting the importance of immune modulation in radioresistance. The study concludes that the integration of RSI and FUSCC TNBC subtypes can refine recurrence risk assessment and inform personalized radiotherapy approaches for high-risk TNBC patients. [Extracted from the article]